Irritable Bowel Syndrome News

Transcutaneous electrical acustimulation improved abdominal pain and constipation symptoms in patients with irritable bowel syndrome compared with a sham procedure, according to a study published in American Journal of Gastroenterology.

Ironwood Pharmaceuticals Inc. announced positive results from its phase 3 trial that evaluated Linzess for the treatment of pediatric patients with functional constipation, according to a company press release.

Although the FDA has granted tentative approval to Norwich Pharmaceuticals’ 200 mg generic rifaximin, Bausch Health asserted in a company statement that full approval will not be given until its own rifaximin patent expires in 2029.

Internet-delivered cognitive behavioral therapy may be a cost-effective solution to improve symptoms and quality of life in patients with irritable bowel syndrome, according to a systematic review in Journal of Medical Internet Research.

The AGA has issued clinical guidelines that outline a pharmacologic treatment plan for patients with irritable bowel syndrome and its subtypes, IBS-constipation and IBS-diarrhea, which were published in Gastroenterology.

Here are Healio’s top 10 peer-tested articles from Digestive Disease Week 2022, which highlight research on restrictive diets, gallstone disease, dog ownership and Crohn’s disease, COVID-19 antibody response and more.

We have long known that our diets affect our health, but many questions remain about diet’s impact on conditions like cancer and its potential value in treating a wide variety of health conditions.

SAN DIEGO — An investigational, point-of-care rectal expulsion device may help determine whether patients with chronic constipation will improve with pelvic floor physical therapy, according to data presented at Digestive Disease Week 2022.

SAN DIEGO — Two restrictive diets were superior in reducing symptoms compared with optimized medical treatment alone in patients with irritable bowel syndrome, according to results presented at Digestive Disease Week 2022.

SAN DIEGO — A smartphone app using artificial intelligence was more effective than patient reporting in assessing stool samples in a cohort of individuals with irritable bowel syndrome, according to data presented at Digestive Diseases Week.